Abstract
Apathy, one of the most prevalent neuropsychiatric symptoms in Alzheimer's Disease (AD), contributes significantly to further decline in cognition and function. Emerging evidence supports the use of methylphenidate (MPH) for the treatment of apathy. However, psychostimulants, which increase central dopamine concentrations, are known to play a role in modulating attention and reward salience. The goal of this study was to investigate the effects of MPH on attention and the relationship between MPH effects on apathy and attention.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
